{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:00:48Z","timestamp":1776398448078,"version":"3.51.2"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00256-021-03771-2","type":"journal-article","created":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T07:02:47Z","timestamp":1617519767000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of FDG PET in the staging of multiple myeloma"],"prefix":"10.1007","volume":"51","author":[{"given":"Joao R. T.","family":"Vicentini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam A.","family":"Bredella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,4]]},"reference":[{"issue":"12","key":"3771_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"key":"3771_CR2","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","volume":"36","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016;36:e418\u201323.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"3771_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","volume":"18","author":"GA Edelstyn","year":"1967","unstructured":"Edelstyn GA, Gillespie PJ, Grebbell FS. The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol. 1967;18(2):158\u201362.","journal-title":"Clin Radiol"},{"issue":"6","key":"3771_CR4","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M-V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302\u201312.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3771_CR5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","volume":"159","author":"E Zamagni","year":"2012","unstructured":"Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(5):499\u2013513.","journal-title":"Br J Haematol"},{"issue":"4","key":"3771_CR6","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206\u201317.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3771_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-016-3502-6","volume":"44","author":"C Sachpekidis","year":"2017","unstructured":"Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, et al. Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging. 2017;44(1):50\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3771_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1148\/rg.242025724","volume":"24","author":"V Kapoor","year":"2004","unstructured":"Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. RadioGraphics. 2004;24(2):523\u201343.","journal-title":"RadioGraphics."},{"issue":"1025","key":"3771_CR9","doi-asserted-by":"publisher","first-page":"20120570","DOI":"10.1259\/bjr.20120570","volume":"86","author":"C Buchbender","year":"2013","unstructured":"Buchbender C, Hartung-Knemeyer V, Forsting M, Antoch G, Heusner TA. Positron emission tomography (PET) attenuation correction artefacts in PET\/CT and PET\/MRI. Br J Radiol. 2013;86(1025):20120570.","journal-title":"Br J Radiol"},{"issue":"Suppl 1","key":"3771_CR10","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S\u201320S.","journal-title":"J Nucl Med"},{"key":"3771_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/CGM.S16817","volume":"7","author":"A Hameed","year":"2014","unstructured":"Hameed A, Brady JJ, Dowling P, Clynes M, O\u2019Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014;7:33\u201342.","journal-title":"Cancer Growth Metastasis"},{"issue":"3","key":"3771_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cpet.2019.03.009","volume":"14","author":"GC Seval","year":"2019","unstructured":"Seval GC, Ozkan E, Beksac M. PET with Fluorodeoxyglucose F 18\/computed tomography as a staging tool in multiple myeloma. PET Clin. 2019;14(3):369\u201381.","journal-title":"PET Clin"},{"issue":"12","key":"3771_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s00256-002-0580-2","volume":"31","author":"H Jadvar","year":"2002","unstructured":"Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skelet Radiol. 2002;31(12):690\u20134.","journal-title":"Skelet Radiol"},{"issue":"11","key":"3771_CR14","first-page":"1457","volume":"43","author":"BGM Durie","year":"2002","unstructured":"Durie BGM, Waxman AD, D\u2019Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43(11):1457\u201363.","journal-title":"J Nucl Med"},{"issue":"4","key":"3771_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","volume":"184","author":"MA Bredella","year":"2005","unstructured":"Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol. 2005;184(4):1199\u2013204.","journal-title":"Am J Roentgenol"},{"issue":"6C","key":"3771_CR16","first-page":"4737","volume":"25","author":"G-U Hung","year":"2005","unstructured":"Hung G-U, Tsai C-C, Tsai S-C, Lin W-Y. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Res. 2005;25(6C):4737\u201341.","journal-title":"Anticancer Res"},{"issue":"9","key":"3771_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00256-006-0127-z","volume":"35","author":"RJ Breyer","year":"2006","unstructured":"Breyer RJ, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET\/CT with other imaging modalities in myeloma. Skelet Radiol. 2006;35(9):632\u201340.","journal-title":"Skelet Radiol"},{"issue":"5","key":"3771_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-005-0004-3","volume":"33","author":"C Nanni","year":"2006","unstructured":"Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33(5):525\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3771_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50\u20135.","journal-title":"Haematologica."},{"issue":"7","key":"3771_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00256-010-1088-9","volume":"40","author":"S Sager","year":"2011","unstructured":"Sager S, Erg\u00fcl N, Ciftci H, Cetin G, G\u00fcner S\u0130, Cermik TF. The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skelet Radiol. 2011;40(7):843\u20137.","journal-title":"Skelet Radiol"},{"issue":"4","key":"3771_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/02841850801898625","volume":"49","author":"J Hur","year":"2008","unstructured":"Hur J, Yoon C-S, Hoon Ryu Y, Yun MJ, Suh J-S. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma. Acta Radiol. 2008;49(4):427\u201335.","journal-title":"Acta Radiol"},{"issue":"2","key":"3771_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2967\/jnumed.107.045641","volume":"49","author":"R Fonti","year":"2008","unstructured":"Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, et al. 18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49(2):195\u2013200.","journal-title":"J Nucl Med"},{"key":"3771_CR23","doi-asserted-by":"publisher","unstructured":"Shortt CP, Gleeson TG, Breen KA, McHugh J, O\u2019Connell MJ, O\u2019Gorman PJ, Eustace SJ. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. Am J Roentgenol. 2009;192(4):980\u20136. https:\/\/doi.org\/10.2214\/AJR.08.1633.","DOI":"10.2214\/AJR.08.1633"},{"issue":"3","key":"3771_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2214\/AJR.18.20989","volume":"213","author":"J Chen","year":"2019","unstructured":"Chen J, Li C, Tian Y, Xiao Q, Deng M, Hu H, et al. Comparison of whole-body DWI and 18 F-FDG PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma. Am J Roentgenol. 2019;213(3):514\u201323.","journal-title":"Am J Roentgenol"},{"issue":"6","key":"3771_CR25","first-page":"536","volume":"54","author":"Z Adam","year":"2007","unstructured":"Adam Z, Bolcak K, Stanicek J, Buchler T, Pour L, Krejci M, et al. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance. Neoplasma. 2007;54(6):536\u201340.","journal-title":"Neoplasma."},{"issue":"1","key":"3771_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjh.12346","volume":"162","author":"JC Regelink","year":"2013","unstructured":"Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters van den Bos IC, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013;162(1):50\u201361.","journal-title":"Br J Haematol"},{"issue":"1","key":"3771_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0b013e3181c3619c","volume":"35","author":"M Castellani","year":"2010","unstructured":"Castellani M, Carletto M, Baldini L, Calori R, Longari V, Soligo D, et al. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. Clin Nucl Med. 2010;35(1):1\u20135.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"3771_CR28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","volume":"37","author":"Y-Y Lu","year":"2012","unstructured":"Lu Y-Y, Chen J-H, Lin W-Y, Liang J-A, Wang H-Y, Tsai S-C, et al. FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833\u20137.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"3771_CR29","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2214\/AJR.08.1633","volume":"192","author":"CP Shortt","year":"2009","unstructured":"Shortt CP, Gleeson TG, Breen KA, McHugh J, O\u2019Connell MJ, O\u2019Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. Am J Roentgenol. 2009;192(4):980\u20136.","journal-title":"Am J Roentgenol"},{"issue":"2","key":"3771_CR30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00330-012-2600-5","volume":"23","author":"T Derlin","year":"2013","unstructured":"Derlin T, Peldschus K, M\u00fcnster S, Bannas P, Herrmann J, St\u00fcbig T, et al. Comparative diagnostic performance of 18F-FDG PET\/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol. 2013;23(2):570\u20138.","journal-title":"Eur Radiol"},{"issue":"8","key":"3771_CR31","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","volume":"118","author":"D van Lammeren-Venema","year":"2012","unstructured":"van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118(8):1971\u201381.","journal-title":"Cancer."},{"issue":"22","key":"3771_CR32","doi-asserted-by":"publisher","first-page":"9879","DOI":"10.7314\/APJCP.2014.15.22.9879","volume":"15","author":"W-W Weng","year":"2014","unstructured":"Weng W-W, Dong M-J, Zhang J, Yang J, Xu Q, Zhu Y-J, et al. A systematic review of MRI, scintigraphy, FDG-PET and PET\/CT for diagnosis of multiple myeloma related bone disease - which is best? Asian Pac J Cancer Prev. 2014;15(22):9879\u201384.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3771_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.02.012","volume":"124","author":"J Gariani","year":"2018","unstructured":"Gariani J, Westerland O, Natas S, Verma H, Cook G, Goh V. Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography\/CT (18F-FDG PET\/CT) in patients with myeloma: systematic review of diagnostic performance. Crit Rev Oncol Hematol. 2018;124:66\u201372.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"3771_CR34","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068\u201376.","journal-title":"Blood."},{"issue":"23","key":"3771_CR35","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989\u201395.","journal-title":"Blood."},{"issue":"6","key":"3771_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","volume":"38","author":"R Haznedar","year":"2011","unstructured":"Haznedar R, Ak\u0131 SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Ya\u011fc\u0131 M, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3771_CR37","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","volume":"21","author":"F Patriarca","year":"2015","unstructured":"Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1068\u201373.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"3771_CR38","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, et al. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384\u201390.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3771_CR39","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","volume":"53","author":"R Fonti","year":"2012","unstructured":"Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829\u201335.","journal-title":"J Nucl Med"},{"issue":"17","key":"3771_CR40","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.18632\/oncotarget.2290","volume":"5","author":"C Lapa","year":"2014","unstructured":"Lapa C, L\u00fcckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, et al. 18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5(17):7381\u201391.","journal-title":"Oncotarget."},{"issue":"3","key":"3771_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00259-011-1993-8","volume":"39","author":"T Derlin","year":"2012","unstructured":"Derlin T, Weber C, Habermann CR, Herrmann J, Wisotzki C, Ayuk F, et al. 18F-FDG PET\/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39(3):493\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3771_CR42","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1016\/j.ejrad.2012.06.028","volume":"81","author":"P Spinnato","year":"2012","unstructured":"Spinnato P, Bazzocchi A, Brioli A, Nanni C, Zamagni E, Albisinni U, et al. Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012;81(12):4013\u20138.","journal-title":"Eur J Radiol"},{"issue":"25","key":"3771_CR43","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [ 18 F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. JCO. 2017;35(25):2911\u20138.","journal-title":"JCO."},{"issue":"10","key":"3771_CR44","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819\u201323.","journal-title":"Blood."},{"issue":"2","key":"3771_CR45","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1097\/RLU.0b013e318266cee2","volume":"38","author":"C Nanni","year":"2013","unstructured":"Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET\/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38(2):e74\u20139.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"3771_CR46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/RLU.0b013e3181b06bc5","volume":"34","author":"A Dimitrakopoulou-Strauss","year":"2009","unstructured":"Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34(9):576\u201384.","journal-title":"Clin Nucl Med"},{"issue":"21","key":"3771_CR47","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1182\/blood.V124.21.3983.3983","volume":"124","author":"M Beksac","year":"2014","unstructured":"Beksac M, Gunduz M, Ozen M, Bakanay Ozturk SM, Kucuk O, Ozkan E. Impact of PET-CT response on survival parameters following autologous stem cell transplantation among patients with multiple myeloma: comparison of two cut-off values. Blood. 2014;124(21):3983.","journal-title":"Blood."},{"issue":"8","key":"3771_CR48","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"key":"3771_CR49","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1038\/bcj.2015.87","volume":"5","author":"B Siontis","year":"2015","unstructured":"Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015;5:e364.","journal-title":"Blood Cancer J"},{"issue":"2","key":"3771_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bell\u00f2 M, et al. 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417\u201322.","journal-title":"Leukemia."},{"issue":"5","key":"3771_CR51","first-page":"841","volume":"18","author":"H Schirrmeister","year":"2003","unstructured":"Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm. 2003;18(5):841\u20135.","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"3771_CR52","first-page":"513","volume":"22","author":"C Nanni","year":"2008","unstructured":"Nanni C, Rubello D, Zamagni E, Castellucci P, Ambrosini V, Montini G, et al. 18F-FDG PET\/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513\u20137.","journal-title":"In Vivo"},{"issue":"8","key":"3771_CR53","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3324\/haematol.12654","volume":"93","author":"P-Y Salaun","year":"2008","unstructured":"Salaun P-Y, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bod\u00e9r\u00e9-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269\u201371.","journal-title":"Haematologica."},{"issue":"7","key":"3771_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.23201","volume":"87","author":"R Warsame","year":"2012","unstructured":"Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87(7):647\u201351.","journal-title":"Am J Hematol"},{"issue":"12","key":"3771_CR55","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","volume":"20","author":"G Fouquet","year":"2014","unstructured":"Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, et al. Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254\u201360.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3771_CR56","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","volume":"83","author":"C Mesguich","year":"2014","unstructured":"Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings. Eur J Radiol. 2014;83(12):2203\u201323.","journal-title":"Eur J Radiol"},{"issue":"1","key":"3771_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-014-0308-3","volume":"15","author":"F Dammacco","year":"2015","unstructured":"Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. 18F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15(1):1\u201318.","journal-title":"Clin Exp Med"},{"issue":"5","key":"3771_CR58","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-021-03771-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-021-03771-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-021-03771-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T14:14:59Z","timestamp":1724768099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-021-03771-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,4]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3771"],"URL":"https:\/\/doi.org\/10.1007\/s00256-021-03771-2","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,4]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}